广西新诊断多发性骨髓瘤临床诊疗路径  

Clinical pathway for diagnosis and treatment of new diagnosed multiple myeloma in Guangxi

作　　者：广西血液内科专业医疗质量控制中心,广西浆细胞疾病协作组 The Control Center of Medical Quality of Guangxi Hematology,Guangxi Plasma Cell Disease Collaboration Group

机构地区：[1]不详

出　　处：《广西医科大学学报》2025年第2期315-322,共8页Journal of Guangxi Medical University

基　　金：国家自然科学基金地区科学基金项目(No.81660038)。

摘　　要：多发性骨髓瘤是一种克隆浆细胞异常增殖的恶性疾病,是血液系统第2位常见恶性肿瘤,目前仍无法治愈。规范化诊疗对延长患者的生存,提高其生活质量具有重要意义。考虑到广西独特的经济、文化、地域及新药可及性等特点,制定与之相匹配的诊疗路径十分必要。因此,广西血液内科专业医疗质量控制中心及广西浆细胞疾病协作组参考国内外指南和专家共识,制定了本临床诊疗路径。Multiple myeloma,an incurable clonal plasma cell dysplasia,is the second most common hematological malignancy.Standardized diagnosis and treatment are crucial for prolonging the survival of myeloma patients and improving the quality of their lives.There is a need to develop a diagnosis and treatment pathway to match the unique economic,cultural,regional characteristics and new drugs available in Guangxi.Therefore,the Control Center of Medical Quality of Guangxi Hematology and the Guangxi Plasma Cell Disease Collaboration Group have,based on the guidelines and expert consensus at home and abroad,developed this clinical diagnosis and treatment pathway.

关 键 词：多发性骨髓瘤 浆细胞 诊断 治疗路径 

分 类 号：R552[医药卫生—血液循环系统疾病]